Australia's most trusted
source of pharma news
Friday, 14 February 2025
Posted 19 September 2023 AM
Ex-pharma exec turned venture capitalist, Andrew Wilks, says local commercial opportunities need to be better understood after GSK scored FDA approval for a bone marrow cancer drug he discovered.
Over the weekend, the US regulator approved the JAK inhibitor momelotinib, branded Ojjaara (and renamed Omjarra), to treat intermediate or high-risk myelofibrosis in patients with anaemia.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.